Fund A Cure is an special entity and unique to JDRF's Gala program. The monetary amount given is at the donor's discretion. Patrons are welcome to make a Fund A Cure donation prior to the gala.
Fund A Cure donations over the years have helped thrust what were once just concepts into a reality. One of the key therapies JDRF is focused on is Encapsulation. Through support from dedicated donors, JDRF-funded partner ViaCyte, has for the first time ever, implanted a person with type 1 diabetes (T1D) with an experimental encapsulated cell replacement therapy called VC-01™. The person is participating in a trial to evaluate the safety and efficacy of the VC-01 product candidate, a potential replacement source of insulin-producing cells.
Encapsulated cell replacement therapies have the potential to fundamentally transform the management of T1D by restoring a person’s independence from insulin injections. The stem cell-derived cells are designed to replace a person’s lost insulin-producing ability while being protected from the ongoing T1D autoimmune attack.
This day would not have been possible without JDRF-funded years of stem cell research and the insights learned to protect them from the autoimmune attack.
Fund A Cure donations are 100% tax deductible, with all proceeds directly benefiting type 1 diabetes (T1D) research.
JDRF thanks you for your support!